cbdMD (NYSEAMERICAN:YCBD) Stock Price Down 0.1% – Time to Sell?

Shares of cbdMD, Inc. (NYSEAMERICAN:YCBD) were down 0.1% during mid-day trading on Friday . The company traded as low as $0.56 and last traded at $0.5650. Approximately 105,812 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 245,720 shares. The stock had previously closed at $0.5657.

cbdMD Stock Performance

The stock has a 50-day simple moving average of $0.65 and a 200 day simple moving average of $0.75.

cbdMD (NYSEAMERICAN:YCBD) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). cbdMD had a negative net margin of 13.29% and a negative return on equity of 33.60%. The firm had revenue of $5.64 million during the quarter, compared to analyst estimates of $5.29 million.

Institutional Trading of cbdMD

A hedge fund recently bought a new stake in cbdMD stock. Jane Street Group LLC purchased a new stake in cbdMD, Inc. (NYSEAMERICAN:YCBD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,141 shares of the company’s stock, valued at approximately $69,000. Jane Street Group LLC owned about 0.49% of cbdMD as of its most recent filing with the Securities and Exchange Commission (SEC). 7.18% of the stock is currently owned by institutional investors.

cbdMD Company Profile

cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.